Biotech Values

[DewDiligence]

>MNTA – it is simpler to state Case 1 or 2: 65%<

The distinction between case 1 and case 2 matters greatly because the economics of the Lovenox collaboration with Sandoz are much more favorable to MNTA if they have the only generic on the market.

If Sandoz/MNTA have the only generic Lovenox on the market, the Lovenox collaboration becomes an equal or near-equal profit split. On the other hand, if Teva or Amphastar launch a generic Lovenox, instead of a profit split, MNTA gets royalties on Sandoz’s sales at a relatively low rate.